Form 4: Terns Pharmaceuticals CEO Amy L. Burroughs Acquires Shares

Terns Pharmaceuticals CEO Amy L. Burroughs acquired 15,450 shares of common stock on December 5, 2024, including shares from the company's Employee Stock Purchase Plan.

Summary

• Amy L. Burroughs, CEO of Terns Pharmaceuticals, acquired 15,450 shares of common stock on December 5, 2024.
• The purchase was made at a price of $7.15 per share.
• This transaction increased her total direct holdings to 19,099 shares.
• The acquisition includes 3,649 shares obtained through the company's 2021 Employee Stock Purchase Plan (ESPP) on November 30, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as the CEO's purchase indicates confidence, but it's a routine transaction.

Positives

• The CEO's purchase of shares can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine SEC Form 4 filing, which is common for company executives who trade their company's stock. It provides transparency into insider transactions.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and this transaction is consistent with standard practices.
• Executives often participate in stock purchase plans and make open market purchases, similar to this transaction by Amy L. Burroughs.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement for all publicly traded companies.

Stakeholder Impact

• The CEO's stock purchase may positively influence investor confidence.

Key Dates

Keywords

Terns Pharmaceuticals, Amy L. Burroughs, insider trading, stock purchase, common stock, ESPP, executive